ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, is pleased to announce that the company has accepted an invitation to exhibit at the 7th McKinsey Global Integrated Care Conference to be held at The Westin, Sydney on the 16th and 17th of November. The theme of the Conference is “Getting to the Next Generation of Integrated Care” and will feature a Digital Health Gallery showcasing technologies that have the potential to disrupt and improve healthcare delivery. Attendees will include global hospital board members and CEOs, clinical leaders, national policy makers and national / regional payors.
“This is a fantastic opportunity for the Company to showcase its smartphone-based respiratory disease diagnostic test to high-level industry participants,” said Dr Tony Keating, CEO and Managing Director of ResApp.
The Company is also pleased to announce that Dr Keating will be accompanying Dr Udantha Abeyratne, Associate Professor in Biomedical Engineering at The University of Queensland and Chief Scientific Advisor at ResApp, to the Pneumonia Innovations Summit to be held on November 12th in New York City. Dr Keating will also meet with interested investors and industry analysts as well as present to the Harvard Investors Group, a prestigious group of qualified investors and investment professionals.
– ENDS –
About ResApp Health Limited
Founded in 2014, ResApp Health Limited, through an exclusive license granted by the University of Queensland (UQ) is developing smartphone medical applications for the diagnosis and management of respiratory disease. The technology is based on a machine learning algorithm that uses sound alone without the need for additional hardware to diagnose and measure the severity of a respiratory condition. The algorithms have been successfully tested for pneumonia and asthma diagnosis in a clinical proof of concept study by UQ through funding from the Bill and Melinda Gates Foundation. Addressable markets for this technology include licensing to large telehealth service providers for ‘in consultation’ point of care diagnosis, at-home diagnosis and management of respiratory disease through direct sales to consumers and healthcare providers, and working with global aid and humanitarian organisations to deliver tools for low-cost diagnosis in the developing world.
For more information on ResApp, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.